Seeking Alpha

Cyclacel Pharmaceuticals jumps on Janney initiation

  • Cyclacel Pharmaceuticals (CYCC) rises 5% premarket (on top of 10% in Monday's regular session) in what looks like a reaction to an initiation (Buy) at Janney Montgomery.
  • Price target is $10.
  • Bullish call is more than likely tied to the company's Phase 3 AML candidate sapacitabine.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs